Nielsen
ceo
2A Pharma
Sweden
Biography
Aalborg University professor Søren Nielsen, MD, dr.med. is one of the world's leading scientists in the field of cellular/molecular biology, physiological and pathological studies of aquaporins, sodium channels and transporters with more than 380 articles published. He brings to 2A Pharma also invaluable business knowledge through Action Pharma A/S where he was co-founder and Executive (CEO 2001-2010, COO 2010-2012) and raised EUR 30 million to conduct clinical trials (Phase 2a & 2b) with AP214 – a candidate for acute renal failure – in Europe and the United States. AP214 was acquired in May 2012 by Abbott, Chicago (~ $ 110 million). For his research, he has received several awards, including the Novo Nordisk Prize, the Novo Nordisk Foundation 2009.
Research Interest
Aalborg University professor Søren Nielsen, MD, dr.med. is one of the world's leading scientists in the field of cellular/molecular biology, physiological and pathological studies of aquaporins, sodium channels and transporters with more than 380 articles published. He brings to 2A Pharma also invaluable business knowledge through Action Pharma A/S where he was co-founder and Executive (CEO 2001-2010, COO 2010-2012) and raised EUR 30 million to conduct clinical trials (Phase 2a & 2b) with AP214 – a candidate for acute renal failure – in Europe and the United States. AP214 was acquired in May 2012 by Abbott, Chicago (~ $ 110 million). For his research, he has received several awards, including the Novo Nordisk Prize, the Novo Nordisk Foundation 2009.
